Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa

Peter T. Manyike, Sanet Aspinall*, Robert S. Summers

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B®; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).

Original languageEnglish
Pages (from-to)726-730
Number of pages5
JournalPediatric Infectious Disease Journal
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 1992

Keywords

  • Black children
  • Hepatitis B vaccine
  • Immunogenicity

Fingerprint

Dive into the research topics of 'Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa'. Together they form a unique fingerprint.

Cite this